Search

The therapeutic management strategy is based on the regular evaluation of the control of asthmatic disease, with an effective minimum dose research and the assessment of environmental factors, not to mention the important place of therapeutic education. These professional recommendations relate to the management and follow-up of adult and adolescent asthma patients aged 12 and over. The recommendations answer the following questions: 1. How to make the initial diagnosis of asthma? 2. What allergological check-up should be done in asthmatics 3. How to manage an asthma exacerbation? 4. How to manage difficult asthma? 5. What therapeutic strategies? 6. How to manage a woman's asthma during pregnancy? 7. Environmental factors in asthma management review., Competing Interests: Declaration of Competing Interest Over the last 5 years, M. Russier has received fees or funding for participation in conferences, communications, training activities, participation in expert panels from Astra Zeneca, Chiesi, Novartis and Sanofi. Over the last 5 years, M. Russier was principal investigator of clinical studies sponsored by AstraZeneca. Over the last 5 years, A. Lorenzo has received the following from Novartis: ERS congress invitation. Over the last 5 years, C. RAHERISON SEMJEN has received fees or funding for participation in conferences, communications, training activities, counselling, participation in expert panels, research activities from ALK, Astra Zeneca, Boeringher Ingelheim, Chiesi, GSK, Novartis and Sanofi. Over the last 5 years, L. Guilleminault has received fees or funding for participation in conferences, communications, training activities, research activities, participation in expert panels, writing of articles or documents, counselling and expertises from ALK, AstraZeneca, Bayer, Chiesi, GlaxoSmithKline, MSD, Novartis, Sanofi and Stallergènes. Over the last 5 years, I. BILLIART has received fees or funding for participation in training activities and expert panels from Novartis, GSK and AstraZeneca. Over the last 5 years, Cécile Chenivesse has received fees or funding from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKlein, Nouveau Souffle, Novartis, Sanofi-Regeneron, Pierre Fabre, Pfizer, Roche, Santelys and TEVA Over the last 5 years, C. Nocent-Ejnain has received fees or funding for participation in conferences, communications, training activities, counselling, participation in expert panels from GSK, AstraZeneca, Novartis, ALK, Mundipharma, Chiesi, Menhari, Sanofi, Isis Medical and sos oxygene. Over the last 5 years, A. DIDIER has received fees or funding for participation in conferences, participation in expert panels, counselling and expertise missions from AstraZeneca, GSK, Chiesi, Stallergènes, ALK, Novartis, Boehringer Ingelheim, BMS, Menarini, Sanofi and Zambon. The other authors state that they have no links of interest. The document was reviewed by the Scientific Council of the SPLF (B. Maitre, C. Leroyer) and the members of the review group: B. Stach, P. Bonniaud, D. Holtea, L. Portel., (Copyright © 2022 SPLF and Elsevier Masson SAS. All rights reserved.)

Background: The aim of ESCAP-2011-CPHG, promoted by the French College of General Hospital Respiratory Physicians, was to describe therapeutic strategies in lung cancer in the first 2 years after diagnosis, in a real-life setting. This article focuses on patients undergoing surgical management of a non-small cell lung cancer (NSCLC)., Methods: A prospective multicentre study was conducted in 53 French general hospitals. For each patient with lung cancer diagnosed in 2010, a standardised form was completed following each change in treatment strategy up to 2 years after diagnosis., Results: Overall, 3418 of the 3943 included patients had NSCLC. 741 patients (21.7%) underwent curative surgery (stage 0-II, IIIA, IIIB, and IV: 65%, 27%, 3% and 5%, respectively). The therapeutic strategy changed less often in surgical than non-surgical patients and average follow-up time was longer: 23.3 months (SD: 9.3) versus 10.4 months (SD: 9.5) for non-surgical patients. Among patients with a surgical first strategy (92.6% of surgical patients as a whole), 56.9% did not receive any other treatment, 34.7% received chemotherapy, 5.9% radio-chemotherapy, 2.6% radiotherapy. At the end of follow-up, 55.8% were still alive without any other strategy, 13.1% had died, and 31.1% had received at least one more strategy. Among patients with a surgical second strategy, 63% had received chemotherapy alone during the first strategy., Conclusions: ESCAP -2011- CPHG assessed everyday professional practice in the surgical management of NSCLC in general hospitals. It pointed out the discrepancies between current guidelines and the therapeutic strategies applied in real life conditions., (Copyright © 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved.)